Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 87 positions · Total reported value $1.29B · Top-10 concentration 39.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, Soleus Capital Management, L.P. disclosed 87 equity positions with a combined reported value of $1.29B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 39.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were XBI ($88.92M), IOVA ($80.08M), TGTX ($59.28M). By sector, the heaviest allocations are Health Care 76.4%, Industrials 1.7%. Versus the prior quarter, allocation shifted toward Other (+1.7pp) and away from Health Care (-2.0pp).

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 64% of names.

The largest new positions opened in Q3 2024 were XBI ($88.92M), GRFS ($40.15M), QDEL ($31.28M).

Of the 27 positions fully exited versus the prior quarter, the largest were PEN ($22.22M), HUM ($16.57M), TEVA ($9.53M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • XBI SPDR SERIES TRUST · $88.92M
  • GRFS GRIFOLS S A · $40.15M
  • QDEL QUIDELORTHO CORP · $31.28M
  • LLY ELI LILLY & CO · $17.10M
  • ANIP ANI PHARMACEUTICALS INC · $16.05M
  • ELV ELEVANCE HEALTH INC FORMERLY · $15.42M
  • LBPH LONGBOARD PHARMACEUTICALS IN · $10.61M
  • TAK TAKEDA PHARMACEUTICAL CO LTD · $7.11M

Fully Exited (vs previous quarter)

  • PEN PENUMBRA INC · prev qtr: $22.22M
  • HUM HUMANA INC · prev qtr: $16.57M
  • TEVA TEVA PHARMACEUTICAL INDS LTD · prev qtr: $9.53M
  • AVDL AVADEL PHARMACEUTICALS · prev qtr: $7.16M
  • CVRX CVRX INC · prev qtr: $7.04M
  • HIMS HIMS & HERS HEALTH INC · prev qtr: $6.72M
  • GMED GLOBUS MED INC · prev qtr: $5.89M
  • JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $5.76M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 76.4%
Materials 0.3%
Other 21.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 900.00K $88.92M 6.88%
6.88%
New
2 8.53M $80.08M 6.20%
6.20%
Add
3 2.53M $59.28M 4.59%
4.59%
Reduce
4 6.22M $51.90M 4.02%
4.02%
Add
5 3.01M $42.14M 3.26%
3.26%
Reduce
6 4.52M $40.15M 3.11%
3.11%
New
7 216.98K $39.50M 3.06%
3.06%
Add
8 6.60M $37.64M 2.92%
2.92%
Add
9 101.89K $36.51M 2.83%
2.83%
Reduce
10 612.00K $35.27M 2.73%
2.73%
Add
11 11.84M $33.86M 2.62%
2.62%
Add
12 1.05M $33.24M 2.57%
2.57%
Add
13 704.58K $31.95M 2.47%
2.47%
Reduce
14 686.00K $31.28M 2.42%
2.42%
New
15 4.29M $25.99M 2.01%
2.01%
Add
16 1.34M $25.27M 1.96%
1.96%
Add
17 637.70K $24.73M 1.92%
1.92%
Reduce
18 1.07M $23.95M 1.85%
1.85%
Reduce
19 951.00K $21.47M 1.66%
1.66%
Add
20 1.09M $21.00M 1.63%
1.63%
Add
21 398.32K $19.90M 1.54%
1.54%
Add
22 662.33K $18.89M 1.46%
1.46%
Reduce
23 7.31M $18.64M 1.44%
1.44%
Hold
24 82.75K $18.58M 1.44%
1.44%
Reduce
25 1.25M $18.57M 1.44%
1.44%
Add
26 19.30K $17.10M 1.32%
1.32%
New
27 2.43M $16.96M 1.31%
1.31%
Hold
28 1.04M $16.81M 1.30%
1.30%
Reduce
29 59.40K $16.34M 1.26%
1.26%
Reduce
30 269.00K $16.05M 1.24%
1.24%
New
31 29.65K $15.42M 1.19%
1.19%
New
32 934.79K $15.12M 1.17%
1.17%
Reduce
33 259.40K $14.93M 1.16%
1.16%
Reduce
34 224.60K $13.04M 1.01%
1.01%
Add
35 340.58K $12.85M 0.99%
0.99%
Reduce
36 7.29M $12.03M 0.93%
0.93%
Hold
37 1.42M $11.62M 0.90%
0.90%
Add
38 598.17K $11.08M 0.86%
0.86%
Add
39 318.27K $10.61M 0.82%
0.82%
New
40 606.93K $9.48M 0.73%
0.73%
Add
41 2.83M $8.46M 0.66%
0.66%
Add
42 785.55K $8.14M 0.63%
0.63%
Reduce
43 288.94K $7.83M 0.61%
0.61%
Reduce
44 93.03K $7.77M 0.60%
0.60%
Reduce
45 74.36K $7.61M 0.59%
0.59%
Reduce
46 302.50K $7.56M 0.58%
0.58%
Add
47 4.04M $7.19M 0.56%
0.56%
Reduce
48 500.00K $7.11M 0.55%
0.55%
New
49 910.00K $6.44M 0.50%
0.50%
New
50 285.00K $6.24M 0.48%
0.48%
New

FAQ

What did Soleus Capital Management, L.P. buy in 2024-Q3?

In its 2024-Q3 13F filing, Soleus Capital Management, L.P. reported 87 equity positions worth $1.29B in aggregate; its largest disclosed positions were XBI ($88.92M), IOVA ($80.08M), TGTX ($59.28M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $1.29B of long equity holdings across 87 positions as of 2024-Q3. Top-10 holdings account for 39.6% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →